| Literature DB >> 32300035 |
Sergio A Castillo-Torres1, Carlos A Soto-Rincón2, Héctor J Villarreal-Montemayor2, Beatriz Chávez-Luévanos2.
Abstract
Neurotoxicity from intrathecally administered chemotherapeutic drugs is frequent, particularly with some agents like methotrexate, which are more prone to developing adverse effects. Myelopathy ranks among the most frequently reported neurological entities; with the diagnosis being straightforward, after ruling out infectious, metabolic, autoimmune or paraneoplastic causes. Scarcity of cases precludes evidence-based recommendations for the management of these complications. The most common therapeutic approach consists of the suspension of chemotherapy, exclusion of infectious and neoplastic causes, with prompt administration of high-dose steroids. We report a 21-year-old patient with acute lymphoblastic leukaemia, who developed acute transverse myelitis and bilateral sensorineural hearing loss, after five rounds of intrathecal methotrexate and cytarabine. Although neurotoxicity from both agents has been documented, this combination has not been previously reported. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: chemotherapy; haematology (incl blood transfusion); neurology (drugs and medicines); spinal cord
Mesh:
Year: 2020 PMID: 32300035 PMCID: PMC7199178 DOI: 10.1136/bcr-2019-234076
Source DB: PubMed Journal: BMJ Case Rep ISSN: 1757-790X